Mixed
SGLT2 inhibitors significantly reduce the risk of hospitalization for heart failure and cardiovascular death in patients with type 2 diabetes, regardless of baseline glycemic control or heart failure status.
If you have Type 2 Diabetes and Heart Failure (or high risk for it), ask your doctor about SGLT2 inhibitors (like Jardiance or Farxiga). These drugs have strong evidence for reducing hospitalizations for heart failure and cardiovascular death, independent of their blood sugar-lowering effects. They are now a standard part of heart failure treatment guidelines.
Multiple landmark clinical trials support their effectiveness in reducing blood glucose levels. In addition, SGLT2 inhibitors have shown favorable effects on body weight (BW), blood pressure (BP), lipid profile, arterial stiffness, and endothelial function. More impressively, they have demonstrated significant cardioprotective and renoprotective effects... The EMPA-REG OUTCOME trial showed that empagliflozin reduced the composite of CV mortality or HHF by 34%, and HHF by 35% in patients with T2D and CV disease.
Why this rating
Based on multiple large-scale Randomized Clinical Trials (RCTs) like EMPA-REG, CANVAS, DAPA-HF.
Source
Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism
Chih‐Neng Hsu et al. · Life · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →